Speaker Profile

Ph.D., Professor; Laboratory Director, Stanford

Biography
Dr. Stuart A. Scott is certified by the American Board of Medical Genetics and Genomics (ABMGG) in Clinical Molecular Genetics and Clinical Cytogenetics, and his research interests include clinical genomics, pharmacogenomics, cytogenomics, long-read sequencing, and the implementation of genomic medicine. Dr. Scott is a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC), PharmGKB, ClinGen, PharmCAT, PharmVar, International Union of Basic and Clinical Pharmacology (IUPHAR), and other international genomics consortia, and has co-authored pharmacogenetic-guided practice guidelines for warfarin, clopidogrel, SSRIs, and voriconazole therapy. He has published over 120 peer-reviewed manuscripts and book chapters on clinical genomics, pharmacogenomics, and genomic medicine implementation, and is the co-editor of the 2nd edition of Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation. He currently oversees genomic test development and implementation at the Stanford Medicine Clinical Genomics Laboratory.

Talk
Clinical Pharmacogenomic Testing: Innovations in Design and Technology
This presentation will identify currently available resources to support clinical pharmacogenomic testing, with an emphasis on reviewing innovative technologies that interrogate germline variation implicated in drug response variability and evaluating best practices for implementing clinical pharmacogenomic testing.


 Session Abstract – PMWC 2022 Silicon Valley


Track Chairs:
Philip Empey, UPitt
Mary V. Relling, St. Jude Children’s Research Hospital
Stuart Scott, Stanford

Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.

  • Keynote: The Future Of PGx
    - Julie Johnson, University of Florida
  • PGx Research and Discovery
    - Estenab Burchard, UCSF
    - William Evans, St. Jude's
    - Jose Estabil, Cipherome
    - James Coons, UPMC
    - Todd Skaar, Indiana University
  • Innovative Industry Solutions
    - Jeffrey A. Shaman, Coriell Life Sciences
    - Akwasi Asabere, Helix
    - Gillian Bell, Genome Medical
    - Cindy Kosinski, 23andme
  • Key Resources for PGx
    - Kelly E. Caudle, St. Jude Children’s Research Hospital
    - Michelle Whirl-Carillo, Stanford
  • Clinical Laboratory PGx Considerations
    - Ulrich Broeckel, MCW
    - Stuart Scott, Stanford
    - Victoria Pratt, Indiana University
  • Lessons from Frontline PGx Clinical Services
    - Mark H. Dunnenberger, Northshore University HealthSystem
    - Lucas Berenbrok, UPitt
    - Sony Tuteja, UPenn
    - Burns Blaxall, The Christ Hospital Health Network
  • Translational PGx Implementation Programs
    - Philip Empey, UPitt
    - Julie A. Johnson, Uinversity of Florida
    - Mary V. Relling, St. Jude Children’s Research Hospital
    - Laura Ramsey, Cincinnati Children's Hospital
    - Nita A. Limdi, UAB